慢性眼移植物抗宿主病的临床特点及相关机制的新进展

赵文心; 梁凌毅

doi:10.3969/j.issn.1674-7445.2022.02.006

慢性眼移植物抗宿主病的临床特点及相关机制的新进展

doi: 10.3969/j.issn.1674-7445.2022.02.006

赵文心,
梁凌毅^,

510060 广州，中山大学中山眼科中心眼科学国家重点实验室广东省眼科视觉科学重点实验室

基金项目:

国家自然科学基金 82070922

详细信息

作者简介:

通讯作者:
梁凌毅，Email：lingyiliang@qq.com

中图分类号: R617, R552, R246.82
计量
- 文章访问数: 582
- HTML全文浏览量: 135
- PDF下载量: 99
- 被引次数: 0
出版历程
- 收稿日期: 2021-12-01
- 网络出版日期: 2022-03-18
- 刊出日期: 2022-03-15

New progress on clinical characteristics and related mechanisms of chronic ocular graft-versus-host disease

Zhao Wenxin,
Liang Lingyi^,

Zhongshan Ophthalmic Center, Sun Yat-sen University, State Key Laboratory of Ophthalmology, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou 510060, China

More Information

Corresponding author: Liang Lingyi, Email: lingyiliang@qq.com

摘要

摘要: 异基因造血干细胞移植（allo-HSCT）可有效治疗多种血液病，目前随着移植技术的不断提高和经济水平的飞速发展，越来越多的血液病患者因接受了allo-HSCT治疗而得以长期存活。慢性眼移植物抗宿主病（coGVHD）是allo-HSCT术后最常见的眼部并发症，主要表现为难治性干眼，严重时可导致眼表稳态失衡、角膜缘干细胞缺乏而出现角膜穿孔、睑球粘连等威胁视功能和眼健康的一系列并发症，治疗十分棘手。目前，国际上对coGVHD的临床表现、诊断标准、治疗规范、致病机制的研究逐步深入，而国内的研究及临床规范的建立尚处于起步阶段。本文对coGVHD的临床特点和相关机制的研究进展进行综述，以期加深眼科医师尤其角膜眼表疾病专科医师对该病的认识，为今后的深入研究提供新的思路。
- 慢性眼移植物抗宿主病（coGVHD） /
- 异基因造血干细胞移植（allo-HSCT） /
- 睑板腺功能障碍 /
- 人工泪液 /
- B细胞活化因子 /
- 眼相关淋巴组织（EALT） /
- 白细胞介素1受体拮抗剂 /
- 脾酪氨酸激酶
Abstract: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) could effectively treat multiple hematological diseases. At present, with persistent improvement of transplantation techniques and rapid development of economy, more and more patients with hematological diseases are able to survive for a long time due to allo-HSCT treatment. Chronic ocular graft-versus-host disease (coGVHD) is the most common ocular complication after allo-HSCT, which is primarily manifested with refractory dry eye. In severe cases, it may cause imbalance of ocular surface homeostasis and limbal stem cell insufficiency, further leading to a series of complications that threaten the visual function and eye health, such as corneal perforation and symblepharon, etc. It is highly difficult to cure these symptoms. At present, relevant studies of clinical manifestations, diagnostic criteria, treatment specification and pathogenesis of coGVHD have been gradually deepened within the international community. However, related research and the establishment of clinical specification are still in the primary stage in China. In this article, research progress on clinical characteristics and related mechanisms of coGVHD was reviewed, aiming to deepen the understanding of this disease by ophthalmologists, especially specialists in corneal and ocular surface diseases, and provide novel ideas for subsequent in-depth research.

HTML全文

下载: 全尺寸图片幻灯片

参考文献(52)

[1]	XU LP, LU PH, WU DP, et al. Hematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group[J]. Bone Marrow Transplant, 2021, 56(12): 2940-2947. DOI: 10.1038/s41409-021-01431-6.
[2]	INAMOTO Y, VALDÉS-SANZ N, OGAWA Y, et al. Ocular graft-versus-host disease after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT[J]. Bone Marrow Transplant, 2019, 54(5): 662-673. DOI: 10.1038/s41409-018-0340-0.
[3]	CHHABRA S, JERKINS JH, CONTO JE, et al. Lifitegrast ophthalmic solution for treatment of ocular chronic graft-versus-host disease[J]. Leuk Lymphoma, 2020, 61(4): 869-874. DOI: 10.1080/10428194.2019.1695049.
[4]	KEZIC JM, WIFFEN S, DEGLI-ESPOSTI M. Keeping an 'eye' on ocular GVHD[J]. Clin Exp Optom, 2021: 1-8. DOI: 10.1080/08164622.2021.1971047.
[5]	QIU Y, HONG J, PENG R. Manifestation of clinical categories of ocular graft-versus-host disease[J]. J Ophthalmol, 2018: 6430953. DOI: 10.1155/2018/6430953.
[6]	OGAWA Y, OKAMOTO S, WAKUI M, et al. Dry eye after haematopoietic stem cell transplantation[J]. Br J Ophthalmol, 1999, 83(10): 1125-1130. DOI: 10.1136/bjo.83.10.1125.
[7]	GIANNACCARE G, BONIFAZI F, SESSA M, et al. Ocular surface analysis in hematological patients before and after allogeneic hematopoietic stem cell transplantation: implication for daily clinical practice[J]. Eye (Lond), 2017, 31(10): 1417-1426. DOI: 10.1038/eye.2017.78.
[8]	BERCHICCI L, RABIOLO A, MARCHESE A, et al. Ocular chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation in an Italian referral center[J]. Ocul Surf, 2018, 16(3): 314-321. DOI: 10.1016/j.jtos.2018.04.001.
[9]	WANG JCC, MUSTAFA M, TEICHMAN JC, et al. Risk factors associated with severity of dry eye syndrome in ocular graft-versus-host disease[J]. Can J Ophthalmol, 2020, 55(5): 366-372. DOI: 10.1016/j.jcjo.2020.04.013.
[10]	PELLEGRINI M, BERNABEI F, BARBATO F, et al. Incidence, risk factors and complications of ocular graft-versus-host disease following hematopoietic stem cell transplantation[J]. Am J Ophthalmol, 2021, 227: 25-34. DOI: 10.1016/j.ajo.2021.02.022.
[11]	JAGASIA MH, GREINIX HT, ARORA M, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: Ⅰ. the 2014 Diagnosis and Staging Working Group report[J]. Biol Blood Marrow Transplant, 2015, 21(3): 389-401. DOI: 10.1016/j.bbmt.2014.12.001.
[12]	OGAWA Y, KIM SK, DANA R, et al. International Chronic Ocular Graft-vs-Host-Disease (GVHD) Consensus Group: proposed diagnostic criteria for chronic GVHD (Part Ⅰ)[J]. Sci Rep, 2013, 3: 3419. DOI: 10.1038/srep03419.
[13]	RAPOPORT Y, FREEMAN T, KOYAMA T, et al. Validation of International Chronic Ocular Graft-Versus-Host Disease (GVHD) Group diagnostic criteria as a chronic ocular GVHD-specific metric[J]. Cornea, 2017, 36(2): 258-263. DOI: 10.1097/ICO.0000000000001109.
[14]	WOLFF D, RADOJCIC V, LAFYATIS R, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: Ⅳ. the 2020 highly morbid forms report[J]. Transplant Cell Ther, 2021, 27(10): 817-835. DOI: 10.1016/j.jtct.2021.06.001.
[15]	李植源. 角膜神经性疼痛研究新进展[J]. 眼科学报, 2021, 36(5): 356-363. DOI: 10.3978/j.issn.1000-4432.2021.04.05. LI ZY. New progress in the study of neuropathic corneal pain[J]. Eye Sci, 2021, 36(5): 356-363. DOI: 10.3978/j.issn.1000-4432.2021.04.05.
[16]	NAIR S, VANATHI M, MUKHIJA R, et al. Update on ocular graft-versus-host disease[J]. Indian J Ophthalmol, 2021, 69(5): 1038-1050. DOI: 10.4103/ijo.IJO_2016_20.
[17]	廖颖琳. 地夸磷索钠治疗干眼的作用机制及其临床应用[J]. 眼科学报, 2021, 36(4): 288-292. DOI: 10.3978/j.issn.1000-4432.2021.03.012. LIAO YL. Mechanism and clinical application of diquafosol tetrasodium in dry eye treatment[J]. Eye Sci, 2021, 36(4): 288-292. DOI: 10.3978/j.issn.1000-4432.2021.03.012.
[18]	SHAMLOO K, BARBARINO A, ALFURAIH S, et al. Graft versus host disease-associated dry eye: role of ocular surface mucins and the effect of rebamipide, a mucin secretagogue[J]. Invest Ophthalmol Vis Sci, 2019, 60(14): 4511-4519. DOI: 10.1167/iovs.19-27843.
[19]	SINGH RB, YUNG A, COCO G, et al. Efficacy and retention of silicone punctal plugs for treatment of dry eye in patients with and without ocular graft-versus-host-disease[J]. Ocul Surf, 2020, 18(4): 731-735. DOI: 10.1016/j.jtos.2020.07.018.
[20]	BEYLERIAN M, LAZARO M, MAGALON J, et al. Autologous serum tears: long-term treatment in dry eye syndrome[J]. J Fr Ophtalmol, 2018, 41(3): 246-254. DOI: 10.1016/j.jfo.2017.11.008.
[21]	MARTÍNEZ-CARRASCO R, SÁNCHEZ-ABARCA LI, NIETO-GÓMEZ C, et al. Subconjunctival injection of mesenchymal stromal cells protects the cornea in an experimental model of GVHD[J]. Ocul Surf, 2019, 17(2): 285-294. DOI: 10.1016/j.jtos.2019.01.001.
[22]	ZHOU T, HE C, LAI P, et al. MiR-204-containing exosomes ameliorate GVHD-associated dry eye disease[J]. Sci Adv, 2022, 8(2): eabj9617. DOI: 10.1126/sciadv.abj9617.
[23]	张暖, 罗晓慧. 间充质干细胞在眼表疾病治疗中的应用[J]. 眼科学报, 2021, 36(4): 299-305. DOI: 10.3978/j.issn.1000-4432.2020.07.11. ZHANG N, LUO XH. Application of mesenchymal stem cells in the treatment of ocular diseases[J]. Eye Sci, 2021, 36(4): 299-305. DOI: 10.3978/j.issn.1000-4432.2020.07.11.
[24]	PERIC Z, SKEGRO I, DURAKOVIC N, et al. Amniotic membrane transplantation-a new approach to crossing the HLA barriers in the treatment of refractory ocular graft-versus-host disease[J]. Bone Marrow Transplant, 2018, 53(11): 1466-1469. DOI: 10.1038/s41409-018-0140-6.
[25]	JARADE EF, EL RAMI H, ABDELMASSIH Y, et al. Chronic ocular GVHD: limbal and conjunctival stem cell allografts from the same hematopoietic stem cell donor[J]. Int J Ophthalmol, 2018, 11(9): 1569-1572. DOI: 10.18240/ijo.2018.09.24.
[26]	CHEUNG AY, GENEREUX BM, AUTERI NJ, et al. Conjunctival-limbal allografts in graft-versus-host disease using same HLA-identical bone marrow transplantation donor[J]. Can J Ophthalmol, 2018, 53(3): e120-e122. DOI: 10.1016/j.jcjo.2017.09.004.
[27]	BRUSCOLINI A, GHARBIYA M, SACCHETTI M, et al. Involvement of ocular surface in graft-versus-host disease: an update from immunopathogenesis to treatment[J]. J Cell Physiol, 2021, 236(9): 6190-6199. DOI: 10.1002/jcp.30304.
[28]	COOKE KR, LUZNIK L, SARANTOPOULOS S, et al. The biology of chronic graft-versus-host disease: a task force report from the National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease[J]. Biol Blood Marrow Transplant, 2017, 23(2): 211-234. DOI: 10.1016/j.bbmt.2016.09.023.
[29]	OGAWA Y, KAWAKAMI Y, TSUBOTA K. Cascade of inflammatory, fibrotic processes, and stress-induced senescence in chronic GVHD-related dry eye disease[J]. Int J Mol Sci, 2021, 22(11): 6114. DOI: 10.3390/ijms22116114.
[30]	KUSNE Y, TEMKIT M, KHERA N, et al. Conjunctival subepithelial fibrosis and meibomian gland atrophy in ocular graft-versus-host disease[J]. Ocul Surf, 2017, 15(4): 784-788. DOI: 10.1016/j.jtos.2017.08.002.
[31]	NAIR S, VANATHI M, MAHAPATRA M, et al. Tear inflammatory mediators and protein in eyes of post allogenic hematopoeitic stem cell transplant patients[J]. Ocul Surf, 2018, 16(3): 352-367. DOI: 10.1016/j.jtos.2018.04.007.
[32]	YEHUDAI-OFIR D, HENIG I, ZUCKERMAN T. Aberrant B cells, autoimmunity and the benefit of targeting B cells in chronic graft-versus-host disease[J]. Autoimmun Rev, 2020, 19(4): 102493. DOI: 10.1016/j.autrev.2020.102493.
[33]	ZHANG C, TODOROV I, ZHANG Z, et al. Donor CD4⁺ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations[J]. Blood, 2006, 107(7): 2993-3001. DOI: 10.1182/blood-2005-09-3623.
[34]	NAKASONE H, TIAN L, SAHAF B, et al. Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans[J]. Blood, 2015, 125(20): 3193-3201. DOI: 10.1182/blood-2014-11-613323.
[35]	YANG K, CHEN Y, QI H, et al. Anti-Ro52 autoantibodies are related to chronic graft-vs.-host disease after allogeneic hematopoietic stem cell transplantation[J]. Front Immunol, 2020, 11: 1505. DOI: 10.3389/fimmu.2020.01505.
[36]	SVEGLIATI S, OLIVIERI A, CAMPELLI N, et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease[J]. Blood, 2007, 110(1): 237-241. DOI: 10.1182/blood-2007-01-071043.
[37]	BRINK R. Regulation of B cell self-tolerance by BAFF[J]. Semin Immunol, 2006, 18(5): 276-283. DOI: 10.1016/j.smim.2006.04.003.
[38]	SAMY E, WAX S, HUARD B, et al. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases[J]. Int Rev Immunol, 2017, 36(1): 3-19. DOI: 10.1080/08830185.2016.1276903.
[39]	JIA W, POE JC, SU H, et al. BAFF promotes heightened BCR responsiveness and manifestations of chronic GVHD after allogeneic stem cell transplantation[J]. Blood, 2021, 137(18): 2544-2557. DOI: 10.1182/blood.2020008040.
[40]	SARANTOPOULOS S, STEVENSON KE, KIM HT, et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease[J]. Clin Cancer Res, 2007, 13(20): 6107-6114. DOI: 10.1158/1078-0432.CCR-07-1290.
[41]	SARANTOPOULOS S, STEVENSON KE, KIM HT, et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease[J]. Blood, 2009, 113(16): 3865-3874. DOI: 10.1182/blood-2008-09-177840.
[42]	FLYNN R, ALLEN JL, LUZNIK L, et al. Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease[J]. Blood, 2015, 125(26): 4085-4094. DOI: 10.1182/blood-2014-08-595470.
[43]	POE JC, JIA W, DI PAOLO JA, et al. Syk inhibitor entospletinib prevents ocular and skin GVHD in mice[J]. JCI Insight, 2018, 3(19): e122430. DOI: 10.1172/jci.insight.122430.
[44]	KUZMINA Z, GREINIX HT, WEIGL R, et al. Significant differences in B-cell subpopulations characterize patients with chronic graft-versus-host disease-associated dysgammaglobulinemia[J]. Blood, 2011, 117(7): 2265-2274. DOI: 10.1182/blood-2010-07-295766.
[45]	SARANTOPOULOS S, RITZ J. Aberrant B-cell homeostasis in chronic GVHD[J]. Blood, 2015, 125(11): 1703-1707. DOI: 10.1182/blood-2014-12-567834.
[46]	POE JC, JIA W, SU H, et al. An aberrant Notch2-BCR signaling axis in B cells from patients with chronic GVHD[J]. Blood, 2017, 130(19): 2131-2145. DOI: 10.1182/blood-2017-05-782466.
[47]	DEBUREAUX PE, DE MASSON A, BATTISTELLA M, et al. Chronic graft-versus-host disease and inhibition of interleukin-17: proof of concept in humans[J]. Br J Dermatol, 2020, 182(4): 1038-1041. DOI: 10.1111/bjd.18214.
[48]	PAULSEN F. Functional anatomy and immunological interactions of ocular surface and adnexa[J]. Dev Ophthalmol, 2008, 41: 21-35. DOI: 10.1159/000131068.
[49]	STEVEN P, SCHWAB S, KIESEWETTER A, et al. Disease-specific expression of conjunctiva associated lymphoid tissue (CALT) in mouse models of dry eye disease and ocular allergy[J]. Int J Mol Sci, 2020, 21(20): 7514. DOI: 10.3390/ijms21207514.
[50]	ROZMUS J, KARIMINIA A, ABDOSSAMADI S, et al. Comprehensive B cell phenotyping profile for chronic graft-versus-host disease diagnosis[J]. Biol Blood Marrow Transplant, 2019, 25(3): 451-458. DOI: 10.1016/j.bbmt.2018.11.007.
[51]	AQRAWI LA, GALTUNG HK, GUERREIRO EM, et al. Proteomic and histopathological characterisation of sicca subjects and primary Sjögren's syndrome patients reveals promising tear, saliva and extracellular vesicle disease biomarkers[J]. Arthritis Res Ther, 2019, 21(1): 181. DOI: 10.1186/s13075-019-1961-4.
[52]	HU B, QIU Y, HONG J. Tear cytokine levels in the diagnosis and severity assessment of ocular chronic graft-versus-host disease(GVHD)[J]. Ocul Surf, 2020, 18(2): 298-304. DOI: 10.1016/j.jtos.2019.12.005.